Pasireotide (Signifor): Uses, Dosing, Side Effects, and How It Compares to Hydrocortisone, Prednisone, and Dexamethasone

What Is Pasireotide and How Does It Lower Cortisol?

Pasireotide suppresses cortisol production by binding somatostatin receptors on corticotroph tumor cells, reducing ACTH secretion and therefore adrenal cortisol output. Unlike glucocorticoids, it acts upstream at the pituitary rather than downstream at target tissues. The drug binds sst1, sst2, sst3, and sst5 with high affinity, giving it broader receptor coverage than octreotide (which favors sst2) [1].

The FDA granted approval for the subcutaneous formulation (Signifor) in December 2012 based on the Phase III PASPORT-CUSHINGS trial. That trial enrolled 162 adults with confirmed Cushing's disease, randomized to 0.6 mg or 0.9 mg subcutaneously twice daily for 12 months. At week 26 to 14.6% of patients in the 0.9 mg group and 26.3% of patients in the 0.6 mg group achieved mean urinary free cortisol (UFC) at or below the upper limit of normal [2]. The drug does not cure the underlying corticotroph adenoma; it suppresses excess hormone secretion while the tumor persists.

Signifor LAR (long-acting release) received FDA approval in November 2014 for acromegaly inadequately controlled on surgery or radiation [3]. The monthly IM formulation uses a microsphere depot that delivers pasireotide over 28 days, with steady-state plasma concentrations typically reached after the third injection. Starting doses of 10 mg, 20 mg, or 40 mg are selected based on prior SSA exposure and disease severity.

At the biochemical level, UFC normalization translates to measurable reductions in the clinical features of Cushing's disease: weight, blood pressure, and bone density parameters improve in responders over 6 to 12 months of therapy [2]. Patients who do not normalize UFC by week 12 are unlikely to respond further and should be reassessed for surgical re-exploration or adrenalectomy.

FDA-Approved Dosing: Subcutaneous Signifor vs. Signifor LAR

The two formulations serve different patient populations and carry different titration rules. Matching the formulation to the clinical situation is one of the first decisions a prescribing endocrinologist makes.

Subcutaneous Signifor for Cushing's disease:

The recommended starting dose is 0.6 mg subcutaneously twice daily. If UFC remains above the upper limit of normal and the patient tolerates the starting dose after two months, the prescriber may increase to 0.9 mg twice daily [2]. Doses above 0.9 mg BID are not FDA-approved. Injections rotate across the thigh or abdomen. Patients with moderate hepatic impairment (Child-Pugh B) should start at 0.3 mg BID and not exceed 0.6 mg BID per the FDA label [3].

Signifor LAR for acromegaly:

In patients who have not previously received an SSA, the typical starting dose is 40 mg IM every 28 days. Those switching from octreotide LAR or lanreotide may begin at 20 mg or 40 mg depending on prior disease control. After three months of stable dosing, the dose adjusts based on IGF-1 and GH levels [3].

Patients with severe hepatic impairment (Child-Pugh C) should not receive either formulation. Renal impairment does not require dose adjustment because pasireotide undergoes minimal renal clearance [4].

Hyperglycemia: The Most Clinically Significant Adverse Effect

Pasireotide produces hyperglycemia at much higher rates than other somatostatin analogues, and this requires active management from day one of therapy. In PASPORT-CUSHINGS, 73% of patients developed new or worsened hyperglycemia during the 12-month study period [2].

The mechanism differs from typical drug-induced hyperglycemia. Pasireotide suppresses insulin secretion by binding sst5 on pancreatic beta cells, and it also suppresses glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) secretion, impairing the incretin axis [5]. Standard metformin monotherapy is often insufficient. An Endocrine Society position statement recommends GLP-1 receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors as preferred first-line agents for pasireotide-induced hyperglycemia because they bypass the suppressed beta-cell pathway [6].

Patients should receive fasting glucose and HbA1c testing at baseline, weekly for the first two to three months, and every three months thereafter. Any patient with a fasting glucose above 126 mg/dL or HbA1c above 6.5% at baseline should have a diabetes management plan documented before the first injection [3].

Pasireotide-induced hyperglycemia generally resolves within two weeks of stopping the drug in most patients [5].

Comparing Pasireotide to Glucocorticoids: Mechanism and Clinical Role

Pasireotide and glucocorticoids like hydrocortisone, prednisone, prednisolone, and dexamethasone operate at opposite ends of the hypothalamic-pituitary-adrenal (HPA) axis. Understanding that difference prevents dangerous prescribing errors.

Glucocorticoids replace or supplement cortisol activity. They are the standard of care for adrenal insufficiency (AI), physiologic stress dosing, and inflammatory or autoimmune conditions. Pasireotide reduces endogenous cortisol production. Giving pasireotide to a patient with primary or secondary AI would worsen cortisol deficiency and could precipitate an adrenal crisis.

Glucocorticoid equivalency: The standard reference doses used in clinical practice are [7]:

• Hydrocortisone (Cortef) 20 mg
• Prednisone 5 mg
• Prednisolone 5 mg
• Methylprednisolone 4 mg
• Dexamethasone 0.75 mg

All five are considered equipotent anti-inflammatory doses, though their mineralocorticoid activity and half-lives differ substantially. Hydrocortisone has the highest mineralocorticoid potency of the group; dexamethasone has essentially none. Dexamethasone's 36 to 54 hour biological half-life makes it the preferred agent for HPA axis suppression testing (the overnight 1 mg dexamethasone suppression test) precisely because it does not cross-react with cortisol immunoassays [8].

Prednisone and prednisolone differ by one metabolic step. Prednisone is a prodrug converted to prednisolone in the liver. In patients with severe hepatic dysfunction, prescribers should use prednisolone directly at the same milligram dose, since conversion may be impaired [9].

Pasireotide's role is narrow: confirmed Cushing's disease where surgery has failed or cannot be performed, or acromegaly inadequately controlled after surgery. The Endocrine Society 2015 Clinical Practice Guideline on Cushing's syndrome lists pasireotide as a second-line medical option after surgery, noting that steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) may normalize UFC in a broader proportion of patients [10].

Adrenal Insufficiency Risk During Pasireotide Therapy

Even in patients with Cushing's disease, overcorrection of cortisol is a real hazard. UFC can drop below the normal range, producing clinical AI symptoms: fatigue, nausea, postural hypotension, and hyponatremia.

In PASPORT-CUSHINGS, hypocortisolism occurred in 8% of patients in the 0.9 mg BID group [2]. Patients who develop signs of AI during pasireotide therapy should receive hydrocortisone supplementation, and the pasireotide dose should be reduced or temporarily stopped [3]. The FDA label recommends monitoring for signs of hypocortisolism and giving patients written instructions on stress dosing with hydrocortisone before they begin pasireotide.

This is one of the few clinical scenarios where a patient may simultaneously take pasireotide (to suppress excess ACTH) and hydrocortisone (to replace the cortisol that has been over-suppressed). Doses of 10 to 20 mg hydrocortisone orally may be sufficient in mild cases; physiologic stress requires 50 to 100 mg IV hydrocortisone per standard AI stress-dosing protocols [7].

Other Adverse Effects and Monitoring Requirements

Beyond hyperglycemia and hypocortisolism, pasireotide carries several additional risks that require structured monitoring.

Cardiac. QTc prolongation was observed in PASPORT-CUSHINGS; 0.9 mg BID prolonged the mean QTc by approximately 13.8 milliseconds [2]. The FDA label requires a baseline ECG, repeat ECG after one week of therapy, and periodic monitoring thereafter. Pasireotide is contraindicated in patients with QTc above 470 ms (women) or 450 ms (men) at baseline [3].

Hepatic. Elevations in ALT, AST, and alkaline phosphatase occur in a subset of patients. Liver enzymes should be checked at baseline and every six weeks for the first six months [3].

Gallbladder. Like all SSAs, pasireotide inhibits cholecystokinin release and slows gallbladder emptying, increasing cholelithiasis risk. Baseline and annual ultrasound is recommended [10].

Pituitary tumor size. Pasireotide does not reliably reduce corticotroph tumor volume. An MRI at 6 months and 12 months is standard practice during medical therapy for Cushing's disease [10].

Bradycardia. Sinus bradycardia can occur, particularly in patients already on beta-blockers or non-dihydropyridine calcium channel blockers. Heart rate monitoring at each visit is advisable.

The Endocrine Society Clinical Practice Guideline on Cushing's syndrome states: "We recommend that patients with persistent or recurrent Cushing's disease after surgery be treated by an endocrinologist experienced in managing this condition, and that medical therapy be selected based on individual patient characteristics, comorbidities, and drug availability." [10]

Prednisone, Prednisolone, and Dexamethasone in the Adrenal-Cortisol Context

Prednisone, prednisolone, and dexamethasone are not treatments for Cushing's disease. They are relevant to the adrenal-cortisol topic in two distinct ways: first, as diagnostic tools, and second, as medications that suppress the HPA axis when used chronically, leading to secondary adrenal insufficiency on withdrawal.

Diagnostic use of dexamethasone: The overnight 1 mg dexamethasone suppression test (DST) is the most widely used outpatient screening tool for Cushing's syndrome. A serum cortisol below 1.8 mcg/dL at 8 AM the morning after a 1 mg dose at 11 PM effectively rules out Cushing's syndrome in most patients, with sensitivity above 95% [8]. The Endocrine Society recommends this test along with late-night salivary cortisol and 24-hour UFC as first-line screening [10].

HPA suppression from chronic corticosteroids: Any patient who takes prednisone at 5 mg or more per day for longer than three weeks may develop HPA axis suppression sufficient to cause secondary AI on abrupt withdrawal [11]. The rate of withdrawal after long-term prednisone therapy should be gradual. A typical taper reduces the dose by no more than 10% every one to two weeks once below physiologic replacement levels [11].

Prednisolone carries the same risk. Dexamethasone's long biological half-life (36 to 54 hours) makes it particularly potent at suppressing the HPA axis; even short courses can blunt the morning ACTH surge [8].

Patients who have received high-dose corticosteroids for autoimmune conditions and then develop fatigue, weight loss, and hypotension months after discontinuation should be evaluated for secondary AI with a morning cortisol and, if borderline, a cosyntropin stimulation test.

Pasireotide Drug Interactions

Pasireotide is metabolized minimally by CYP enzymes; the primary elimination route is biliary excretion. Still, several interactions require attention.

Drugs that prolong the QTc interval (quinolone antibiotics, antipsychotics, certain antiemetics) should be used cautiously alongside pasireotide. The combination may produce additive QTc prolongation beyond what either drug causes independently [3].

Cyclosporine has a possible interaction because pasireotide may reduce its absorption; close monitoring of cyclosporine levels is warranted when initiating or discontinuing pasireotide in transplant patients [3].

Because pasireotide can reduce GH and IGF-1 levels significantly in acromegaly patients, the dose of insulin or oral hypoglycemics used for coexisting diabetes may require downward adjustment if GH-related insulin resistance decreases [4].

Bromocriptine and cabergoline are sometimes used alongside pasireotide in Cushing's disease patients with mixed secretory tumors. No pharmacokinetic interaction has been documented, but additive hypotensive effects are plausible [10].

Patient Selection: Who Should Receive Pasireotide?

Pasireotide is appropriate for a specific and narrow subset of patients. The criteria below reflect FDA labeling and Endocrine Society guidance.

Appropriate candidates include adults with confirmed Cushing's disease (elevated UFC on two separate 24-hour collections, elevated late-night salivary cortisol, and a pituitary source on MRI or inferior petrosal sinus sampling) who have failed transsphenoidal surgery or are not surgical candidates. The drug may also be used as a bridge to radiation therapy, since radiosurgery can take 12 to 24 months to normalize cortisol [10].

Pasireotide is not appropriate for: adrenal-dependent Cushing's (adrenocortical adenoma or carcinoma), ectopic ACTH syndrome (where the ACTH source is outside the pituitary), any patient with active hepatic disease, or any patient with a QTc above thresholds listed in the label.

Patients with pre-existing diabetes require especially careful evaluation. Given the 73% hyperglycemia rate in PASPORT-CUSHINGS [2], a documented diabetes management plan co-developed with an endocrinologist familiar with both diabetes and pituitary disease is mandatory before the first dose.

A clinical decision framework for selecting between pasireotide, steroidogenesis inhibitors (osilodrostat, metyrapone, ketoconazole), and adrenalectomy in post-surgical Cushing's disease:

1. UFC normalization urgency (severe hypercortisolism with cardiac or psychiatric crisis): steroidogenesis inhibitor preferred for rapid control, typically achieving UFC normalization within 2 to 4 weeks.
2. Residual pituitary tumor visible on MRI with mild-to-moderate UFC elevation: pasireotide may be trialed for 12 weeks; if UFC does not normalize by week 12, switch strategy.
3. Patient with pre-existing diabetes or HbA1c above 7.0%: favor osilodrostat or metyrapone over pasireotide given hyperglycemia burden.
4. Bilateral adrenalectomy indicated: consider for patients who fail two sequential medical therapies or require rapid cure (e.g., pregnancy with severe Cushing's).

Long-Term Outcomes and Remission Data

The extension phase of PASPORT-CUSHINGS followed patients for up to 24 months. Among those who maintained normal UFC at month 12, approximately 70% sustained normalization through month 24 [2]. Tumor growth or escape from pasireotide suppression is possible; patients who lose UFC control after initial normalization should undergo repeat MRI before continuing therapy at higher doses.

Long-term use raises concerns about ongoing hyperglycemia management. Pasireotide-induced diabetes tends to persist as long as the drug is used and resolves in most patients within two weeks of stopping [5]. Some patients transition to insulin therapy after failing incretin-based oral agents.

Quality of life measures in PASPORT-CUSHINGS improved statistically in responders (those achieving UFC normalization) on CushingQoL scores but did not improve significantly in non-responders [2]. This finding supports using UFC normalization as the primary endpoint guiding treatment decisions rather than partial reductions.

A 2023 real-world analysis published in the Journal of Clinical Endocrinology and Metabolism examined 87 patients with Cushing's disease treated with pasireotide at academic centers in Europe. UFC normalization at 6 months was achieved in 21% of patients at 0.9 mg BID, consistent with PASPORT-CUSHINGS results, with hyperglycemia requiring pharmacotherapy in 68% of the cohort [12].

The Endocrine Society states in its 2015 guideline: "We suggest using pasireotide for patients with Cushing's disease who are not candidates for surgery or who have persistent or recurrent disease after surgery." [10]

How Pasireotide Compares to Osilodrostat and Ketoconazole

Pasireotide acts at the pituitary (ACTH suppression), while osilodrostat and ketoconazole act at the adrenal cortex (steroidogenesis inhibition). This distinction matters when selecting therapy and when interpreting ACTH levels during treatment.

Osilodrostat (Isturisa) received FDA approval in March 2020 based on the LINC-3 trial (N=137), in which 53% of patients with Cushing's disease achieved UFC normalization at week 36 [13]. That response rate exceeds the 15 to 26% range seen with pasireotide in PASPORT-CUSHINGS, which is why current treatment algorithms often favor osilodrostat as a first-line medical option before pasireotide [10].

Ketoconazole, though lacking a formal FDA approval for Cushing's disease (it is used off-label in the United States), normalizes UFC in approximately 50% of patients in published series [14]. Its primary risks are hepatotoxicity and drug-drug interactions via CYP3A4 inhibition.

Pasireotide retains a role in patients with tumors that express sst5 (identified by immunohistochemistry on surgical pathology), in patients who cannot tolerate adrenal-directed agents, and in those where ACTH suppression from the pituitary level is specifically desired to reduce tumor drive.